BioCentury
ARTICLE | Clinical News

Bevasiranib: Phase III started

July 16, 2007 7:00 AM UTC

OPK (formerly Acuity Pharmaceuticals Inc.) began the international Phase III COBALT trial in 330 patients to compare bevasiranib dosed every 8 and 12 weeks vs. Lucentis dosed every 4 weeks. Genente...